2021 Revenues ($USD) : $11,375,892,207
2021 Revenues (foreign currencies) : JP¥1,249,528,000,000
2021 R&D spend : $2,043,781,865
2021 Number of Employees : 15,455
Fiscal Year End : 3/31/2021
Leader : CEO Kenji Yasukawa

Tokyo-based Astellas Pharma had continued success with its Xtandi (enzalutamide) prostate-cancer-treating drug. Other bestsellers include Xospata (gilteritinib) and Padcev (enfortumab vedotin). In addition, Prograf (tacrolimus) also remains a core product in its portfolio. —BB